Home › Research › Biomarkers
Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies
Calum Alexander Hamilton, John O'Brien, Amanda Heslegrave, Rhiannon Laban, Paul Donaghy, Rory Durcan, Sarah Lawley, Nicola Barnett et al.. Psychological medicine, 2023-07-25
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Probable MCI-LB had elevated GFAP (p < 0.001) and NfL (p = 0.012) relative to controls, but not significantly lower Aβ42/40 (p = 0.06). GFAP and p-tau181 were higher in MCI-AD than MCI-LB. GFAP discriminated all MCI subgroups, from controls (AUC of 0.75), but no plasma-based marker effectively differentiated MCI-AD from MCI-LB. NfL correlated with disease severity and increased with MCI progression over time (p = 0.011). Markers of AD and astrocytosis/neurodegeneration are elevated in MCI-LB. GFAP offered similar utility to p-tau181 in distinguishing MCI overall, and its subgroups, from healthy controls.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hamilton, C. A., O'Brien, J., Heslegrave, A., Laban, R., Donaghy, P., Durcan, R., et al. (2023). Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies. Psychological medicine. https://doi.org/10.1017/s0033291723001952
Vancouver
Hamilton CA, O'Brien J, Heslegrave A, Laban R, Donaghy P, Durcan R, et al. Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies. Psychological medicine. 2023. doi:10.1017/s0033291723001952. PMID: 37489795.
BibTeX
@article{hamilton2023-37489795,
author = {Hamilton, Calum Alexander and O'Brien, John and Heslegrave, Amanda and Laban, Rhiannon and Donaghy, Paul and Durcan, Rory and Lawley, Sarah and Barnett, Nicola and others},
title = {{Plasma biomarkers of neurodegeneration in mild cognitive impairment with Lewy bodies}},
journal = {Psychological medicine},
year = {2023},
doi = {10.1017/s0033291723001952},
pmid = {37489795},
url = {https://doi.org/10.1017/s0033291723001952}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Probable MCI-LB had elevated GFAP (p < 0.001) and NfL (p = 0.012) relative to controls, but not significantly lower Aβ42/40 (p = 0.06).
- GFAP and p-tau181 were higher in MCI-AD than MCI-LB.
- GFAP discriminated all MCI subgroups, from controls (AUC of 0.75), but no plasma-based marker effectively differentiated MCI-AD from MCI-LB.
- NfL correlated with disease severity and increased with MCI progression over time (p = 0.011).
- Markers of AD and astrocytosis/neurodegeneration are elevated in MCI-LB.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants55
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 29 of the 56 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Psychological medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 55 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37489795) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 29 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 29 of the 56 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also in Biomarkers
141 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.